NCT07076706

Clinical Trial to Evaluate CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of CG2001 in Chinese Adult Male Participants With Androgenetic Alopecia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 110 (actual)
• Sponsor: Beijing Dayspring Pharmaceutical Technology Co., Ltd · Industry
• Sex: Male
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

The main objectives of this study are to preliminarily evaluate the effectiveness of CG2001 in treating Chinese adult male AGA participants, determine the recommended dose for Phase III clinical studies, and evaluate the safety of CG2001 at the target dose.

Conditions

• Male Pattern of Hair Loss, Androgenic Alopecia
• Androgenetic Alopecia (AGA)

Interventions

Type	Name	Description
DRUG	minoxidil + finasteride	topical foam: 5%minoxidil+0.075%finasteride
DRUG	minoxidil + finasteride	topical foam: 5%minoxidil+0.1%finasteride
DRUG	Placebo foam	Topical placebo foam

Timeline

• Start date: 2024-12-05
• Primary completion: 2025-08-26
• Completion: 2025-09-23
• First posted: 2025-07-22
• Last updated: 2026-03-03

Locations

8 sites across 1 country: China